Online citations, reference lists, and bibliographies.
← Back to Search

3‐Hydroxy‐3‐methylglutaryl CoA Reductase Inhibitors Reduce Serum Triglyceride Levels Through Modulation Of Apolipoprotein C‐III And Lipoprotein Lipase

K. Schoonjans, J. Peinado-Onsurbe, J. C. Fruchart, A. Tailleux, C. Fiévet, J. Auwerx
Published 1999 · Medicine, Biology

Cite This
Download PDF
Analyze on Scholarcy
Share
Statins are hypolipidemic drugs which not only improve cholesterol but also triglyceride levels. Whereas their cholesterol‐reducing effect involves inhibition of de novo biosynthesis of cellular cholesterol through competitive inhibition of its rate‐limiting enzyme 3‐hydroxy‐3‐methylglutaryl CoA reductase, the mechanism by which they lower triglycerides remains unknown and forms the subject of the current study. Treatment of normal rats for 4 days with simvastatin decreased serum triglycerides significantly, whereas it increased high density lipoprotein cholesterol moderately. The decrease in triglyceride concentrations after simvastatin was caused by a reduction in the amount of very low density lipoprotein particles which were of an unchanged lipid composition. Simvastatin administration increased the lipoprotein lipase mRNA and activity in adipose tissue and heart. This effect on lipoprotein lipase was accompanied by decreased mRNA as well as plasma levels of the lipoprotein lipase inhibitor apolipoprotein C‐III. These results suggest that the triglyceride‐lowering effect of statins involves a stimulation of lipoprotein lipase‐mediated clearance of triglyceride‐rich lipoproteins.
This paper references
10.1016/0002-8703(87)90629-6
Plasma high-density lipoprotein concentration and subfraction distribution in relation to triglyceride metabolism.
E. Nikkilä (1987)
10.1016/0003-2697(87)90021-2
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.
P. Chomczyński (1987)
Protein measurement with the Folin phenol reagent.
O. H. Lowry (1951)
Nuclear protein that binds sterol regulatory element of low density lipoprotein receptor promoter. II. Purification and characterization.
X. Wang (1993)
10.1161/01.CIR.97.15.1453
Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)
T. Pedersen (1998)
10.1002/j.1460-2075.1996.tb00918.x
PPARalpha and PPARgamma activators direct a distinct tissue‐specific transcriptional response via a PPRE in the lipoprotein lipase gene.
K. Schoonjans (1996)
Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and its mRNA in rat liver as studied with a monoclonal antibody and a cDNA probe.
L. Liscum (1983)
10.1101/GAD.10.9.1096
ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism.
J. Kim (1996)
10.1074/jbc.272.12.8083
p38 Mitogen-activated Protein Kinase Down-regulates Nitric Oxide and Up-regulates Prostaglandin E2 Biosynthesis Stimulated by Interleukin-1β*
Z. Guan (1997)
10.1016/0026-0495(93)90203-Z
Effect of gemfibrozil on adipose tissue and muscle lipoprotein lipase.
R. Simsolo (1993)
10.1016/S0092-8674(05)80095-9
SREBP-1, a basic-helix-loop-helix-leucine zipper protein that controls transcription of the low density lipoprotein receptor gene
C. Yokoyama (1993)
10.1172/JCI112713
Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo.
H. Ginsberg (1986)
10.1016/S0092-8674(00)80213-5
The SREBP Pathway: Regulation of Cholesterol Metabolism by Proteolysis of a Membrane-Bound Transcription Factor
M. Brown (1997)
10.1172/JCI103182
The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum.
R. Havel (1955)
10.1016/0005-2760(79)90028-6
Effects of ML-236B on cholesterol metabolism in mice and rats: Lack of hypocholesterolemic activity in normal animals
E. Akira (1979)
10.1093/NAR/19.14.3998
36B4 cDNA used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO.
J. Laborda (1991)
Stimulation of fatty acid oxidation by a 3-thia fatty acid reduces triacylglycerol secretion in cultured rat hepatocytes.
S. Skrede (1994)
10.1074/jbc.271.21.12247
A Direct Role for Sterol Regulatory Element Binding Protein in Activation of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Gene (*)
S. Vallett (1996)
Hypolipidemic effect of beta, beta'-methyl-substituted hexadecanedioic acid (MEDICA 16) in normal and nephrotic rats.
J. Bar-Tana (1988)
Localization of 3-hydroxy-3-methylglutaryl CoA reductase and 3-hydroxy-3-methylglutaryl CoA synthase in the rat liver and intestine is affected by cholestyramine and mevinolin.
A. Li (1988)
10.1042/BJ2320229
Characterization of triacylglycerol hydrolase activities in isolated myocardial cells from rat heart.
I. Ramírez (1985)
10.1074/JBC.272.15.10295
Multiple Sequence Elements are Involved in the Transcriptional Regulation of the Human Squalene Synthase Gene*
G. Guan (1997)
10.1073/PNAS.90.24.11603
SREBP-2, a second basic-helix-loop-helix-leucine zipper protein that stimulates transcription by binding to a sterol regulatory element.
X. Hua (1993)
10.1128/MCB.13.8.4753
ADD1: a novel helix-loop-helix transcription factor associated with adipocyte determination and differentiation.
P. Tontonoz (1993)
10.1161/01.CIR.98.23.2513
Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators.
R. Goldberg (1998)
10.1172/JCI111711
Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III.
C. Wang (1985)
10.1073/PNAS.93.2.945
Sterol regulatory element binding protein binds to a cis element in the promoter of the farnesyl diphosphate synthase gene.
J. Ericsson (1996)
10.1073/PNAS.93.3.1049
Sterol regulation of acetyl coenzyme A carboxylase: a mechanism for coordinate control of cellular lipid.
J. M. López (1996)
10.1172/JCI118951
Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a.
H. Shimano (1996)
10.1074/jbc.270.43.25578
Sterol Regulation of Fatty Acid Synthase Promoter
M. Bennett (1995)
10.1016/0005-2760(93)90140-5
An enzymatic explanation of the differential effects of oleate and gemfibrozil on cultured hepatocyte triacylglycerol and phosphatidylcholine biosynthesis and secretion.
R. Lamb (1993)



This paper is referenced by
10.2217/17460875.2.2.197
Pharmacotherapeutic decisions in menopausal women with cardiovascular risk
T. Dayspring (2007)
10.1006/JMBI.2000.4218
Induction of LPL gene expression by sterols is mediated by a sterol regulatory element and is independent of the presence of multiple E boxes.
K. Schoonjans (2000)
Acute antidepressant and anxiolytic effects of simvastatin and its mechanisms in rats.
F. Kilic (2012)
10.1194/JLR.M400486-JLR200
Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease Published, JLR Papers in Press, February 16, 2005. DOI 10.1194/jlr.M400486-JLR200
R. Lane (2005)
10.5923/J.AJMMS.20120202.06
Chronic Simvastatin Treatments Attenuate Ethanol Withdrawal Syndrome in Rats
Marília Martins Silveira Carrocini (2012)
10.1038/s41598-017-05163-w
A Novel Role for RARα Agonists as Apolipoprotein CIII Inhibitors Identified from High Throughput Screening
S. Lee (2017)
10.3945/ajcn.2009.28422
Effects of atorvastatin and n-3 fatty acid supplementation on VLDL apolipoprotein C-III kinetics in men with abdominal obesity.
D. Chan (2010)
lipoprotein lipase expression
Yuanhui Ma (2013)
Sheet 1 of 2 US 6 , 835 , 750 B 1 Neuron cytoplasm Glucose Glucose
(2017)
10.1016/j.febslet.2008.12.050
ApoC‐III gene expression is sharply increased during adipogenesis and is augmented by retinoid X receptor (RXR) agonists
Y. Takahashi (2009)
10.1161/ATVBAHA.108.170530
Atorvastatin and Fenofibrate Have Comparable Effects on VLDL–Apolipoprotein C-III Kinetics in Men With the Metabolic Syndrome
D. Chan (2008)
10.2337/DIACARE.27.6.1358
Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: a potential mechanism to lower plasma triglycerides.
G. Dallinga-Thie (2004)
The Power of Classic Music to Reduce Anxiety in Rats Treated with Simvastatin
Júlia Niehues da Cruz (2011)
10.1128/MCB.01061-10
mTORC2 Is Required for Proliferation and Survival of TSC2-Null Cells
E. Goncharova (2011)
10.1194/JLR.M300309-JLR200
Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia Published, JLR Papers in Press, October 1, 2003. DOI 10.1194/jlr.M300309-JLR200
S. Bilz (2004)
10.1016/J.ATHEROSCLEROSIS.2004.04.003
Atorvastatin improves diabetic dyslipidemia and increases lipoprotein lipase activity in vivo.
J. Schneider (2004)
10.1016/B978-0-12-800263-6.00003-3
Apolipoprotein B-48: a unique marker of chylomicron metabolism.
K. Nakajima (2014)
Identification of Reverb as a physiological repressor of apoC-III gene transcription 1
E. Raspé (2002)
10.3922/J.PSNS.2013.3.19
Adjuvant effects of classical music on simvastatin induced reduction of anxiety but not object recognition memory in rats
Anice Milbratz de Camargo (2013)
10.1097/00005344-200501000-00010
Rosuvastatin Reduces Plasma Lipids by Inhibiting VLDL Production and Enhancing Hepatobiliary Lipid Excretion in ApoE*3-Leiden Mice
D. Delsing (2005)
10.2165/00003495-200464002-00004
Lipaemia, Inflammation and Atherosclerosis: Novel Opportunities in the Understanding and Treatment of Atherosclerosis
A. J. H. H. M. Oostrom (2012)
Manejo farmacológico de las dislipidemias en la prevención de las enfermedades cardiovasculares
Carlos Calvo Monfil (2004)
10.1007/s00204-004-0625-5
Tryptophan–NAD+ pathway metabolites as putative biomarkers and predictors of peroxisome proliferation
J. Delaney (2004)
Dose-Dependent Effect of Rosuvastatin on Very-Low Density Lipoprotein-Apolipoprotein C-III Kinetics in the Metabolic Syndrome
E. Ooi (2008)
10.1080/07853890310011969
Contribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients
I. Lemieux (2003)
10.1248/BPB.30.627
Triglyceride accumulation by peroxisome proliferators in rat hepatocytes.
H. Kawano (2007)
(54) USE OF MEDIUM CHAIN TRIGLYCERIDES FOR THE TREATMENT AND PREVENTION OF ALZHEMIERS DISEASE AND OTHER DISEASES RESULTING FROM REDUCED NEURONAL METABOLISM II
(2017)
10.1016/j.neulet.2006.09.009
Effects of high dose of simvastatin on levels of dopamine and its reuptake in prefrontal cortex and striatum among SD rats
Q. Wang (2006)
Étude des mécanismes athérogènes associés à l'insulino-résistance et l'hypercholestérolémie familiale
J. Hogue (2008)
10.1016/j.tcm.2008.01.001
Cross-talk between statins and PPARalpha in cardiovascular diseases: clinical evidence and basic mechanisms.
R. Paumelle (2008)
10.1007/s00125-006-0261-0
Plasma apolipoprotein A5 and triglycerides in type 2 diabetes
G. Dallinga-Thie (2006)
10.15406/icpjl.2018.06.00169
Morbid obesity and its comorbidities
Julia Peinado Onsurbe (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar